Exploration of the antibody–drug conjugate clinical landscape

References

• Tolcher AW, Carneiro BA, Dowlati A, Razak AR, Chae YK, Villella JA, Coppola S, Englert S, Phillips AC, Souers AJ, et al. A first-in-human study of mirzotamab clezutoclax as monotherapy and in combination with taxane therapy in relapsed/refractory solid tumors: dose escalation results. J Clin Oncol. 2021;39:3015–43. doi:10.1200/JCO.2021.39.15_suppl.3015.
   Web of Science ®Google Scholar
• Sharma M, Carvajal RD, Hanna GJ, Li BT, Moore KN, Pegram MD, Rasco DW, Spira AI, Alonso M, Fang L, et al. Preliminary results from a phase 1/2 study of BDC-1001, a novel HER2 targeting TLR7/8 immune-stimulating antibody conjugate (ISAC), in patients (pts) with advanced HER2-expressing solid tumors. J Clin Oncol. 2021;39(15_suppl):2549–2549. doi:10.1200/JCO.2021.39.15_suppl.2549.
   Web of Science ®Google Scholar
• Sharma S, Li Z, Bussing D, Shah DK. Evaluation of quantitative relationship between target expression and antibody-drug conjugate exposure inside cancer cells. Drug Metab Dispos. 2020;48:368–77. doi:10.1124/dmd.119.089276. PMID: 32086295.
   PubMed Web of Science ®Google Scholar
• Hammood M, Craig AW, Leyton JV. Impact of endocytosis mechanisms for the receptors targeted by the currently approved Antibody-Drug Conjugates (ADCs)-A necessity for future ADC research and development. Pharmaceuticals (Basel). 2021;14 doi:10.3390/ph14070674. PMID: 34358100.
   PubMedGoogle Scholar
• Li JY, Perry SR, Muniz-Medina V, Wang X, Wetzel LK, Rebelatto MC, Hinrichs MJ, Bezabeh BZ, Fleming RL, Dimasi N, et al. A biparatopic HER2-targeting antibody-drug conjugate induces tumor regression in primary models refractory to or ineligible for HER2-targeted therapy. Cancer Cell. 2016;29:117–29. doi:10.1016/j.ccell.2015.12.008. PMID: 26766593.
   PubMed Web of Science ®Google Scholar
• Liang K, Mei S, Gao X, Peng S, Zhan J. Dynamics of endocytosis and degradation of antibody-drug conjugate T-DM1 in HER2 positive cancer cells. Drug Des Devel Ther. 2021;15:5135–50. PMID: 34992350. doi:10.2147/DDDT.S344052.
   PubMed Web of Science ®Google Scholar
• Ogitani Y, Aida T, Hagihara K, Yamaguchi J, Ishii C, Harada N, Soma M, Okamoto H, Oitate M, Arakawa S, et al. DS-8201a, A Novel HER2-targeting ADC with a Novel DNA topoisomerase i inhibitor, demonstrates a promising antitumor efficacy with differentiation from T-DM1. Clin Cancer Res. 2016;22:5097–108. doi:10.1158/1078-0432.CCR-15-2822. PMID: 27026201.
   PubMed Web of Science ®Google Scholar
• Von Minckwitz G, Huang CS, Mano MS, Loibl S, Mamounas EP, Untch M, Wolmark N, Rastogi P, Schneeweiss A, Redondo A, et al. Trastuzumab emtansine for residual invasive HER2-positive breast cancer. N Engl J Med. 2019;380:617–28. doi:10.1056/NEJMoa1814017. PMID: 30516102.
   PubMed Web of Science ®Google Scholar
• Modi S, Saura C, Yamashita T, Park YH, Kim SB, Tamura K, Andre F, Iwata H, Ito Y, Tsurutani J, et al. Trastuzumab deruxtecan in previously treated HER2-positive breast cancer. N Engl J Med. 2020;382:610–21. doi:10.1056/NEJMoa1914510. PMID: 31825192.
   PubMed Web of Science ®Google Scholar
• Anderson MG, Zhang Q, Rodriguez LE, Hecquet CM, Donawho CK, Ansell PJ, Reilly EB. ABBV-176, a PRLR antibody drug conjugate with a potent DNA-damaging PBD cytotoxin and enhanced activity with PARP inhibition. BMC Cancer. 2021;21(1):681.doi:10.1186/s12885-021-08403-5. PMID: 34107902.
   PubMed Web of Science ®Google Scholar
• Lemech C, Woodward N, Chan N, Mortimer J, Naumovski L, Nuthalapati S, Tong B, Jiang F, Ansell P, Ratajczak CK, et al. A first-in-human, phase 1, dose-escalation study of ABBV-176, an antibody-drug conjugate targeting the prolactin receptor, in patients with advanced solid tumors. Invest New Drugs. 2020;38(6):1815–25. doi:10.1007/s10637-020-00960-z. PMID: 32524319.
   PubMed Web of Science ®Google Scholar
• Du X, Beers R, Fitzgerald DJ, Pastan I. Differential cellular internalization of anti-CD19 and -CD22 immunotoxins results in different cytotoxic activity. Cancer Res. 2008;68(15):6300–05.doi:10.1158/0008-5472.CAN-08-0461. PMID: 18676854.
   PubMed Web of Science ®Google Scholar
• Wong OK, Tran -T-T, Ho W-H, Casas MG, Au M, Bateman M, Lindquist KC, Rajpal A, Shelton DL, Strop P, et al. RN765C, a low affinity EGFR antibody drug conjugate with potent anti-tumor activity in preclinical solid tumor models. Oncotarget. 2018;9(71):33446–58. doi:10.18632/oncotarget.26002. PMID: 30323890.
   PubMedGoogle Scholar
• Chen Y, Clark S, Wong T, Chen Y, Chen Y, Dennis MS, Luis E, Zhong F, Bheddah S, Koeppen H, et al. Armed antibodies targeting the mucin repeats of the ovarian cancer antigen, MUC16, are highly efficacious in animal tumor models. Cancer Res. 2007;67(10):4924–32. doi:10.1158/0008-5472.CAN-06-4512. PMID: 17510422.
   PubMed Web of Science ®Google Scholar
• Wang L, Amphlett G, Blattler WA, Lambert JM, Zhang W. Structural characterization of the maytansinoid-monoclonal antibody immunoconjugate, huN901-DM1, by mass spectrometry. Protein Sci. 2005;14(9):2436–46. doi:10.1110/ps.051478705. PMID: 16081651.
   PubMed Web of Science ®Google Scholar
• Hamblett KJ, Senter PD, Chace DF, Sun MM, Lenox J, Cerveny CG, Kissler KM, Bernhardt SX, Kopcha AK, Zabinski RF, et al. Effects of drug loading on the antitumor activity of a monoclonal antibody drug conjugate. Clin Cancer Res. 2004;10(20):7063–70. doi:10.1158/1078-0432.CCR-04-0789. PMID: 15501986.
   PubMed Web of Science ®Google Scholar
• Matsuda Y, Seki T, Yamada K, Ooba Y, Takahashi K, Fujii T, Kawaguchi S, Narita T, Nakayama A, Kitahara Y, et al. Chemical site-specific conjugation platform to improve the pharmacokinetics and therapeutic index of Antibody–Drug conjugates. Mol Pharm. 2021;18(11):4058–66. doi:10.1021/acs.molpharmaceut.1c00473. PMID: 34579528.
   PubMedGoogle Scholar
• Junutula JR, Raab H, Clark S, Bhakta S, Leipold DD, Weir S, Chen Y, Simpson M, Tsai SP, Dennis MS, et al. Site-specific conjugation of a cytotoxic drug to an antibody improves the therapeutic index. Nat Biotechnol. 2008;26(8):925–32. doi:10.1038/nbt.1480. PMID: 18641636.
   PubMed Web of Science ®Google Scholar
• Wynn CP, Patel R, Hillegass WB, Tang ,S-C. Increased systemic toxicities from antibody-drug conjugates (ADCs) with cleavable versus non-cleavable linkers: a meta-analysis of commercially available ADCs. Journal of Clinical Oncology. 2022;40(16_suppl):3032–3032. doi:10.1200/JCO.2022.40.16_suppl.3032.
   PubMed Web of Science ®Google Scholar
• Kovtun YV, Audette CA, Ye Y, Xie H, Ruberti MF, Phinney SJ, Leece BA, Chittenden T, Blattler WA, Goldmacher VS. Antibody-drug conjugates designed to eradicate tumors with homogeneous and heterogeneous expression of the target antigen. Cancer Res. 2006;66(6):3214–21. doi:10.1158/0008-5472.CAN-05-3973. PMID: 16540673.
   PubMed Web of Science ®Google Scholar
• Ogitani Y, Hagihara K, Oitate M, Naito H, Agatsuma T. Bystander killing effect of DS −8201a, a novel anti-human epidermal growth factor receptor 2 antibody–drug conjugate, in tumors with human epidermal growth factor receptor 2 heterogeneity. Cancer Sci. 2016;107(7):1039–46. doi:10.1111/cas.12966. PMID: 27166974.
   PubMed Web of Science ®Google Scholar
• Hurvitz SA, Hegg R, Chung W-P, Im S-A, Jacot W, Ganju V, Chiu JWY, Xu B, Hamilton E, Madhusudan S, et al. Trastuzumab deruxtecan versus trastuzumab emtansine in patients with HER2-positive metastatic breast cancer: updated results from DESTINY-Breast03, a randomised, open-label, phase 3 trial. Lancet. 2023;401(10371):105–17. doi:10.1016/S0140-6736(22)02420-5. PMID: 36495879.
   PubMed Web of Science ®Google Scholar
• Lyon RP, Bovee TD, Doronina SO, Burke PJ, Hunter JH, Neff-LaFord HD, Jonas M, Anderson ME, Setter JR, Senter PD. Reducing hydrophobicity of homogeneous antibody-drug conjugates improves pharmacokinetics and therapeutic index. Nat Biotechnol. 2015;33(7):733–35. doi:10.1038/nbt.3212. PMID: 26076429.
   PubMed Web of Science ®Google Scholar
• Ross HJ, Hart LL, Swanson PM, Rarick MU, Figlin RA, Jacobs AD, McCune DE, Rosenberg AH, Baron AD, Grove LE, et al. A randomized, multicenter study to determine the safety and efficacy of the immunoconjugate SGN-15 plus docetaxel for the treatment of non-small cell lung carcinoma. Lung Cancer. 2006;54(1):69–77. doi:10.1016/j.lungcan.2006.05.020. PMID: 16934909.
   PubMed Web of Science ®Google Scholar
• https://clinicaltrials.gov. [accessed 2023 Jan 1]
   Google Scholar
• Conilh L, Sadilkova L, Viricel W, Dumontet C. Payload diversification: a key step in the development of antibody-drug conjugates. J Hematol Oncol. 2023;16:3. doi:10.1186/s13045-022-01397-y. PMID: 36650546.
   PubMed Web of Science ®Google Scholar
• Hamilton E, O’Malley DM, O’Cearbhaill R, Cristea M, Fleming GF, Tariq B, Fong A, French D, Rossi M, Brickman D, et al. Tamrintamab pamozirine (SC-003) in patients with platinum-resistant/refractory ovarian cancer: findings of a phase 1 study. Gynecol Oncol. 2020;158:640–45. doi:10.1016/j.ygyno.2020.05.038. PMID: 32513564.
   PubMed Web of Science ®Google Scholar
• Johnson ML, Zvirbule Z, Laktionov K, Helland A, Cho BC, Gutierrez V, Colinet B, Lena H, Wolf M, Gottfried M, et al. Rovalpituzumab tesirine as a maintenance therapy after first-line platinum-based chemotherapy in patients with extensive-stage-SCLC: results from the phase 3 MERU study. J Thorac Oncol. 2021;16:1570–81. doi:10.1016/j.jtho.2021.03.012. PMID: 33823285.
   PubMed Web of Science ®Google Scholar
• Blackhall F, Jao K, Greillier L, Cho BC, Penkov K, Reguart N, Majem M, Nackaerts K, Syrigos K, Hansen K, et al. Efficacy and safety of rovalpituzumab tesirine compared with topotecan as second-line therapy in DLL3-high SCLC: results from the phase 3 TAHOE study. J Thorac Oncol. 2021;16:1547–58. doi:10.1016/j.jtho.2021.02.009. PMID: 33607312.
   PubMed Web of Science ®Google Scholar
• Hamilton E, Fleming GF, Thaker PH, Subbiah S, Chen C, Fong A, Brickman D, Moore K. First-in-human study of SC-004, an antibody-drug conjugate targeting CLDN6/9, in patients with epithelial ovarian cancers. Cancer Res. 2020:80. doi:10.1158/1538-7445.AM2020-CT124.
   Google Scholar
• De Bono JS, Fleming MT, Wang JS, Cathomas R, Miralles MS, Bothos J, Hinrichs MJ, Zhang Q, He P, Williams M, et al. Phase I study of MEDI3726: a prostate-specific membrane antigen-targeted antibody-drug conjugate, in patients with mCRPC after failure of abiraterone or enzalutamide. Clin Cancer Res. 2021;27:3602–09. doi:10.1158/1078-0432.CCR-20-4528. PMID: 33795255.
   PubMed Web of Science ®Google Scholar
• Doronina SO, Mendelsohn BA, Bovee TD, Cerveny CG, Alley SC, Meyer DL, Oflazoglu E, Toki BE, Sanderson RJ, Zabinski RF, et al. Enhanced activity of monomethylauristatin F through monoclonal antibody delivery: effects of linker technology on efficacy and toxicity. Bioconjug Chem. 2006;17:114–24. doi:10.1021/bc0502917. PMID: 16417259.
   PubMed Web of Science ®Google Scholar
• Mathijssen RH, van Alphen RJ, Verweij J, Loos WJ, Nooter K, Stoter G, Sparreboom A. Clinical pharmacokinetics and metabolism of irinotecan (CPT-11). Clin Cancer Res. 2001;7:2182–94. https://www.ncbi.nlm.nih.gov/pubmed/11489791. PMID: 11489791.
   PubMed Web of Science ®Google Scholar
• Yu SF, Zheng B, Go M, Lau J, Spencer S, Raab H, Soriano R, Jhunjhunwala S, Cohen R, Caruso M, et al. A Novel anti-CD22 anthracycline-based Antibody-Drug Conjugate (ADC) that overcomes resistance to auristatin-based ADCs. Clin Cancer Res. 2015;21:3298–306. doi:10.1158/1078-0432.CCR-14-2035. PMID: 25840969.
   PubMed Web of Science ®Google Scholar
• Takegawa N, Nonagase Y, Yonesaka K, Sakai K, Maenishi O, Ogitani Y, Tamura T, Nishio K, Nakagawa K, Tsurutani J. DS-8201a, a new HER2-targeting antibody-drug conjugate incorporating a novel DNA topoisomerase I inhibitor, overcomes HER2-positive gastric cancer T-DM1 resistance. Int J Cancer. 2017;141:1682–89. doi:10.1002/ijc.30870. PMID: 28677116.
   PubMed Web of Science ®Google Scholar
• Hull EA, Livanos M, Miranda E, Smith ME, Chester KA, Baker JR. Homogeneous bispecifics by disulfide bridging. Bioconjug Chem. 2014;25:1395–401. doi:10.1021/bc5002467. PMID: 25033024.
   PubMed Web of Science ®Google Scholar
• Jen EY, Ko CW, Lee JE, Del Valle PL, Aydanian A, Jewell C, Norsworthy KJ, Przepiorka D, Nie L, Liu J, et al. FDA approval: gemtuzumab ozogamicin for the treatment of adults with newly diagnosed CD33-positive acute myeloid leukemia. Clin Cancer Res. 2018;24:3242–46. doi:10.1158/1078-0432.CCR-17-3179. PMID: 29476018.
   PubMed Web of Science ®Google Scholar
• https://www.gsk.com/en-gb/media/press-releases/gsk-provides-update-on-blenrep-us-marketing-authorisation/.
   Google Scholar
• Goldenberg DM, Sharkey RM. Antibody-drug conjugates targeting TROP-2 and incorporating SN-38: a case study of anti-TROP-2 sacituzumab govitecan. MAbs. 2019;11:987–95. doi:10.1080/19420862.2019.1632115. PMID: 31208270.
   PubMed Web of Science ®Google Scholar
• Cleary JM, Calvo E, Moreno V, Juric D, Shapiro GI, Vanderwal CA, Hu B, Gifford M, Barch D, Roberts-Rapp L, et al. A phase 1 study evaluating safety and pharmacokinetics of losatuxizumab vedotin (ABBV-221), an anti-EGFR antibody-drug conjugate carrying monomethyl auristatin E, in patients with solid tumors likely to overexpress EGFR. Invest New Drugs. 2020;38:1483–94. doi:10.1007/s10637-020-00908-3. PMID: 32189093.
   PubMed Web of Science ®Google Scholar
• Sandhu S, McNeil CM, LoRusso P, Patel MR, Kabbarah O, Li C, Sanabria S, Flanagan WM, Yeh R-F, Brunstein F, et al. Phase I study of the anti-endothelin B receptor antibody-drug conjugate DEDN6526A in patients with metastatic or unresectable cutaneous, mucosal, or uveal melanoma. Invest New Drugs. 2020;38(3):844–54. doi:10.1007/s10637-019-00832-1. PMID: 31385109.
   PubMed Web of Science ®Google Scholar
• Almhanna K, Wright D, Mercade TM, Van Laethem J-L, Gracian AC, Guillen-Ponce C, Faris J, Lopez CM, Hubner RA, Bendell J, et al. A phase II study of antibody-drug conjugate, TAK-264 (MLN0264) in previously treated patients with advanced or metastatic pancreatic adenocarcinoma expressing guanylyl cyclase C. Invest New Drugs. 2017;35(5):634–41. doi:10.1007/s10637-017-0473-9. PMID: 28527133.
   PubMed Web of Science ®Google Scholar
• Almhanna K, Miron ML, Wright D, Gracian AC, Hubner RA, Van Laethem J-L, Lopez CM, Alsina M, Munoz FL, Bendell J, et al. Phase II study of the antibody-drug conjugate TAK-264 (MLN0264) in patients with metastatic or recurrent adenocarcinoma of the stomach or gastroesophageal junction expressing guanylyl cyclase C. Invest New Drugs. 2017;35(2):235–41. doi:10.1007/s10637-017-0439-y. PMID: 28188407.
   PubMed Web of Science ®Google Scholar
• Hasanov M, Rioth MJ, Kendra K, Hernandez-Aya L, Joseph RW, Williamson S, Chandra S, Shirai K, Turner CD, Lewis K, et al. A phase II study of glembatumumab vedotin for metastatic uveal melanoma. Cancers (Basel). 2020;12(8):2270. doi:10.3390/cancers12082270. PMID: 32823698.
   PubMed Web of Science ®Google Scholar
• Ott PA, Pavlick AC, Johnson DB, Hart LL, Infante JR, Luke JJ, Lutzky J, Rothschild NE, Spitler LE, Cowey CL, et al. A phase 2 study of glembatumumab vedotin, an antibody-drug conjugate targeting glycoprotein NMB, in patients with advanced melanoma. Cancer. 2019;125(7):1113–23. doi:10.1002/cncr.31892. PMID: 30690710.
   PubMed Web of Science ®Google Scholar
• Vahdat LT, Schmid P, Forero-Torres A, Blackwell K, Telli ML, Melisko M, Mobus V, Cortes J, Montero AJ, Ma C, et al. Glembatumumab vedotin for patients with metastatic, gpNMB overexpressing, triple-negative breast cancer (“METRIC”): a randomized multicenter study. NPJ Breast Cancer. 2021;7:57. doi:10.1038/s41523-021-00244-6. PMID: 34016993.
   PubMed Web of Science ®Google Scholar
• Yardley DA, Weaver R, Melisko ME, Saleh MN, Arena FP, Forero A, Cigler T, Stopeck A, Citrin D, Oliff I, et al. EMERGE: a randomized phase II study of the antibody-drug conjugate glembatumumab vedotin in advanced glycoprotein NMB–expressing breast cancer. J Clin Oncol. 2015;33(14):1609–19. doi:10.1200/JCO.2014.56.2959. PMID: 25847941.
   PubMed Web of Science ®Google Scholar
• Kopp LM, Malempati S, Krailo M, Gao Y, Buxton A, Weigel BJ, Hawthorne T, Crowley E, Moscow JA, Reid JM, et al. Phase II trial of the glycoprotein non-metastatic B-targeted antibody–drug conjugate, glembatumumab vedotin (CDX-011), in recurrent osteosarcoma AOST1521: a report from the Children’s oncology group. Eur J Cancer. 2019;121:177–83. doi:10.1016/j.ejca.2019.08.015. PMID: 31586757.
   PubMed Web of Science ®Google Scholar
• Demetri GD, Luke JJ, Hollebecque A, Powderly JD 2nd, Spira AI, Subbiah V, Naumovski L, Chen C, Fang H, Lai DW, et al. First-in-human phase I Study of ABBV-085, an Antibody–Drug conjugate targeting LRRC15, in sarcomas and other advanced solid tumors. Clin Cancer Res. 2021;27(13):3556–66. doi:10.1158/1078-0432.CCR-20-4513. PMID: 33820780.
   PubMed Web of Science ®Google Scholar
• Tolaney SM, Do KT, Eder JP, LoRusso PM, Weekes CD, Chandarlapaty S, Chang C-W, Chen S-C, Nazzal D, Schuth E, et al. A phase I study of DLYE5953A, an anti-LY6E antibody covalently linked to monomethyl auristatin E, in patients with refractory solid tumors. Clin Cancer Res. 2020;26(21):5588–97. doi:10.1158/1078-0432.CCR-20-1067. PMID: 32694157.
   PubMed Web of Science ®Google Scholar
• Weekes CD, Lamberts LE, Borad MJ, Voortman J, McWilliams RR, Diamond JR, De Vries EG, Verheul HM, Lieu CH, Kim GP, et al. Phase I study of DMOT4039A, an Antibody–Drug conjugate targeting mesothelin, in patients with unresectable pancreatic or platinum-resistant ovarian cancer. Mol Cancer Ther. 2016;15(3):439–47. doi:10.1158/1535-7163.MCT-15-0693. PMID: 26823490.
   PubMed Web of Science ®Google Scholar
• Liu JF, Moore KN, Birrer MJ, Berlin S, Matulonis UA, Infante JR, Wolpin B, Poon KA, Firestein R, Xu J, et al. Phase I study of safety and pharmacokinetics of the anti-MUC16 antibody-drug conjugate DMUC5754A in patients with platinum-resistant ovarian cancer or unresectable pancreatic cancer. Ann Oncol. 2016;27:2124–30. doi:10.1093/annonc/mdw401. PMID: 27793850.
   PubMed Web of Science ®Google Scholar
• Liu J, Burris H, Wang JS, Barroilhet L, Gutierrez M, Wang Y, Vaze A, Commerford R, Royer-Joo S, Choeurng V, et al. An open-label phase I dose-escalation study of the safety and pharmacokinetics of DMUC4064A in patients with platinum-resistant ovarian cancer. Gynecol Oncol. 2021;163:473–80. doi:10.1016/j.ygyno.2021.09.023. PMID: 34627611.
   PubMed Web of Science ®Google Scholar
• Banerjee S, Oza AM, Birrer MJ, Hamilton EP, Hasan J, Leary A, Moore KN, Mackowiak-Matejczyk B, Pikiel J, Ray-Coquard I, et al. Anti-NaPi2b antibody-drug conjugate lifastuzumab vedotin (DNIB0600A) compared with pegylated liposomal doxorubicin in patients with platinum-resistant ovarian cancer in a randomized, open-label, phase II study. Ann Oncol. 2018;29:917–23. doi:10.1093/annonc/mdy023. PMID: 29401246.
   PubMed Web of Science ®Google Scholar
• Coveler AL, Ko AH, Catenacci DV, Von Hoff D, Becerra C, Whiting NC, Yang J, Wolpin B. A phase 1 clinical trial of ASG-5ME, a novel drug-antibody conjugate targeting SLC44A4, in patients with advanced pancreatic and gastric cancers. Invest New Drugs. 2016;34(3):319–28.doi:10.1007/s10637-016-0343-x. PMID: 26994014.
   PubMed Web of Science ®Google Scholar
• McHugh D, Eisenberger M, Heath EI, Bruce J, Danila DC, Rathkopf DE, Feldman J, Slovin SF, Anand B, Chu R, et al. A phase I study of the antibody drug conjugate ASG-5ME, an SLC44A4-targeting antibody carrying auristatin E, in metastatic castration-resistant prostate cancer. Invest New Drugs. 2019;37(5):1052–60. doi:10.1007/s10637-019-00731-5. PMID: 30725389.
   PubMed Web of Science ®Google Scholar
• Danila DC, Szmulewitz RZ, Vaishampayan U, Higano CS, Baron AD, Gilbert HN, Brunstein F, Milojic-Blair M, Wang B, Kabbarah O, et al. Phase I study of DSTP3086S, an antibody-drug conjugate targeting six-transmembrane epithelial antigen of prostate 1, in metastatic castration-resistant prostate cancer. J Clin Oncol. 2019;37(36):3518–27. doi:10.1200/JCO.19.00646. PMID: 31689155.
   PubMed Web of Science ®Google Scholar
• McGregor BA, Gordon M, Flippot R, Agarwal N, George S, Quinn DI, Rogalski M, Hawthorne T, Keler T, Choueiri TK. Safety and efficacy of CDX-014, an antibody-drug conjugate directed against T cell immunoglobulin mucin-1 in advanced renal cell carcinoma. Invest New Drugs. 2020;38(6):1807–14.doi:10.1007/s10637-020-00945-y. PMID: 32472319.
   PubMed Web of Science ®Google Scholar
• Morschhauser F, Flinn IW, Advani R, Sehn LH, Diefenbach C, Kolibaba K, Press OW, Salles G, Tilly H, Chen AI, et al. Polatuzumab vedotin or pinatuzumab vedotin plus rituximab in patients with relapsed or refractory non-Hodgkin lymphoma: final results from a phase 2 randomised study (ROMULUS). Lancet Haematol. 2019;6(5):e254–e265. doi:10.1016/S2352-3026(19)30026-2. PMID: 30935953.
   PubMed Web of Science ®Google Scholar
• Herrera AF, Patel MR, Burke JM, Advani R, Cheson BD, Sharman JP, Penuel E, Polson AG, Liao CD, Li C, et al. Anti-CD79B antibody-drug conjugate DCDS0780A in patients with B-cell non-Hodgkin lymphoma: phase 1 dose-escalation study. Clin Cancer Res. 2022;28:1294–301. doi:10.1158/1078-0432.CCR-21-3261. PMID: 34980599.
   PubMed Web of Science ®Google Scholar
• Stewart AK, Krishnan AY, Singhal S, Boccia RV, Patel MR, Niesvizky R, Chanan-Khan AA, Ailawadhi S, Brumm J, Mundt KE, et al. Phase I study of the anti-FcRH5 antibody-drug conjugate DFRF4539A in relapsed or refractory multiple myeloma. Blood Cancer J. 2019;9(2):17. doi:10.1038/s41408-019-0178-8. PMID: 30718503.
   PubMedGoogle Scholar
• Vij R, Nath R, Afar DEH, Mateos M-V, Berdeja JG, Raab MS, Guenther A, Martinez-Lopez J, Jakubowiak AJ, Leleu X, et al. First-in-human phase I study of ABBV-838, an Antibody–Drug conjugate targeting SLAMF7/CS1 in patients with relapsed and refractory multiple myeloma. Clin Cancer Res. 2020;26(10):2308–17. doi:10.1158/1078-0432.CCR-19-1431. PMID: 31969330.
   PubMed Web of Science ®Google Scholar
• Shapiro GI, Vaishampayan UN, LoRusso P, Barton J, Hua S, Reich SD, Shazer R, Taylor CT, Xuan D, Borghaei H. First-in-human trial of an anti-5T4 antibody-monomethylauristatin conjugate, PF-06263507, in patients with advanced solid tumors. Invest New Drugs. 2017;35(3):315–23.doi:10.1007/s10637-016-0419-7. PMID: 28070718.
   PubMed Web of Science ®Google Scholar
• Lassman AB, Pugh SL, Wang TJC, Aldape K, Gan HK, Preusser M, Vogelbaum MA, Sulman EP, Won M, Zhang P, et al. Depatuxizumab mafodotin in EGFR-amplified newly diagnosed glioblastoma: a phase III randomized clinical trial. Neuro Oncol. 2023;25:339–50. doi:10.1093/neuonc/noac173. PMID: 35849035.
   PubMed Web of Science ®Google Scholar
• Kollmannsberger C, Choueiri TK, Heng DYC, George S, Jie F, Croitoru R, Poondru S, Thompson JA. A randomized phase II study of AGS-16C3F versus axitinib in previously treated patients with metastatic renal cell carcinoma. Oncologist. 2021;26:182–e361. doi:10.1002/onco.13628. PMID: 33289953.
   PubMed Web of Science ®Google Scholar
• Annunziata CM, Kohn EC, LoRusso P, Houston ND, Coleman RL, Buzoianu M, Robbie G, Lechleider R. Phase 1, open-label study of MEDI-547 in patients with relapsed or refractory solid tumors. Invest New Drugs. 2013;31:77–84. PMID: 22370972. doi:10.1007/s10637-012-9801-2.
   PubMed Web of Science ®Google Scholar
• Tannir NM, Forero-Torres A, Ramchandren R, Pal SK, Ansell SM, Infante JR, de Vos S, Hamlin PA, Kim SK, Whiting NC, et al. Phase I dose-escalation study of SGN-75 in patients with CD70-positive relapsed/refractory non-Hodgkin lymphoma or metastatic renal cell carcinoma. Invest New Drugs. 2014;32(6):1246–57. doi:10.1007/s10637-014-0151-0. PMID: 25142258.
   PubMed Web of Science ®Google Scholar
• Kim SB, Meric-Bernstam F, Kalyan A, Babich A, Liu R, Tanigawa T, Sommer A, Osada M, Reetz F, Laurent D, et al. First-in-human phase I study of aprutumab ixadotin, a fibroblast growth factor receptor 2 antibody-drug conjugate (BAY 1187982) in patients with advanced cancer. Target Oncol. 2019;14:591–601. doi:10.1007/s11523-019-00670-4. PMID: 31502117.
   PubMed Web of Science ®Google Scholar
• Hamilton EP, Barve MA, Bardia A, Beeram M, Bendell JC, Mosher R, Hailman E, Bergstrom DA, Burris HA, Soliman HH. Phase 1 dose escalation of XMT-1522, a novel HER2-targeting antibody-drug conjugate (ADC), in patients (pts) with HER2-expressing breast, lung and gastric tumors. J Clin Oncol. 2018;36(15_suppl):2546. doi:10.1200/JCO.2018.36.15_suppl.2546.
   Web of Science ®Google Scholar
• Rosen LS, Wesolowski R, Baffa R, Liao K-H, Hua SY, Gibson BL, Pirie-Shepherd S, Tolcher AW. A phase I, dose-escalation study of PF-06650808, an anti-Notch3 antibody–drug conjugate, in patients with breast cancer and other advanced solid tumors. Invest New Drugs. 2020;38(1):120–30.doi:10.1007/s10637-019-00754-y. PMID: 30887250.
   PubMed Web of Science ®Google Scholar
• King GT, Eaton KD, Beagle BR, Zopf CJ, Wong GY, Krupka HI, Hua SY, Messersmith WA, El-Khoueiry AB. A phase 1, dose-escalation study of PF-06664178, an anti-Trop-2/Aur0101 antibody-drug conjugate in patients with advanced or metastatic solid tumors. Invest New Drugs. 2018;36:836–47. doi:10.1007/s10637-018-0560-6. PMID: 29333575.
   PubMed Web of Science ®Google Scholar
• Tolcher AW, Ochoa L, Hammond LA, Patnaik A, Edwards T, Takimoto C, Smith L, de Bono J, Schwartz G, Mays T, et al. Cantuzumab mertansine, a maytansinoid immunoconjugate directed to the CanAg antigen: a phase I, pharmacokinetic, and biologic correlative study. J Clin Oncol. 2003;21(2):211–22. doi:10.1200/JCO.2003.05.137. PMID: 12525512.
   PubMed Web of Science ®Google Scholar
• Helft PR, Schilsky RL, Hoke FJ, Williams D, Kindler HL, Sprague E, DeWitte M, Martino HK, Erickson J, Pandite L, et al. A phase I study of cantuzumab mertansine administered as a single intravenous infusion once weekly in patients with advanced solid tumors. Clin Cancer Res. 2004;10(13):4363–68. doi:10.1158/1078-0432.CCR-04-0088. PMID: 15240523.
   PubMed Web of Science ®Google Scholar
• Riechelmann H, Sauter A, Golze W, Hanft G, Schroen C, Hoermann K, Erhardt T, Gronau S. Phase I trial with the CD44v6-targeting immunoconjugate bivatuzumab mertansine in head and neck squamous cell carcinoma. Oral Oncol. 2008;44:823–29. doi:10.1016/j.oraloncology.2007.10.009. PMID: 18203652.
   PubMed Web of Science ®Google Scholar
• Tijink BM, Buter J, de Bree R, Giaccone G, Lang MS, Staab A, Leemans CR, van Dongen GA. A phase I dose escalation study with anti-CD44v6 bivatuzumab mertansine in patients with incurable squamous cell carcinoma of the head and neck or esophagus. Clin Cancer Res. 2006;12(20):6064–72.doi:10.1158/1078-0432.CCR-06-0910. PMID: 17062682.
   PubMed Web of Science ®Google Scholar
• Socinski MA, Kaye FJ, Spigel DR, Kudrik FJ, Ponce S, Ellis PM, Majem M, Lorigan P, Gandhi L, Gutierrez ME, et al. Phase 1/2 study of the CD56-targeting antibody-drug conjugate lorvotuzumab mertansine (IMGN901) in combination with carboplatin/etoposide in small-cell lung cancer patients with extensive-stage disease. Clin Lung Cancer. 2017;18:68–76 e62. doi:10.1016/j.cllc.2016.09.002. PMID: 28341109.
   PubMed Web of Science ®Google Scholar
• Geller JI, Pressey JG, Smith MA, Kudgus RA, Cajaiba M, Reid JM, Hall D, Barkauskas DA, Voss SD, Cho SY, et al. ADVL1522: a phase 2 study of lorvotuzumab mertansine (IMGN901) in children with relapsed or refractory Wilms tumor, rhabdomyosarcoma, neuroblastoma, pleuropulmonary blastoma, malignant peripheral nerve sheath tumor, or synovial sarcoma-A Children’s Oncology Group study. Cancer. 2020;126(24):5303–10. doi:10.1002/cncr.33195. PMID: 32914879.
   PubMed Web of Science ®Google Scholar
• Massard C, Soria J-C, Krauss J, Gordon M, Lockhart AC, Rasmussen E, Upreti VV, Patel S, Ngarmchamnanrith G, Henary H. First-in-human study to assess safety, tolerability, pharmacokinetics, and pharmacodynamics of the anti-CD27L antibody-drug conjugate AMG 172 in patients with relapsed/refractory renal cell carcinoma. Cancer Chemother Pharmacol. 2019;83(6):1057–63.doi:10.1007/s00280-019-03796-4. PMID: 30915497.
   PubMed Web of Science ®Google Scholar
• L’Italien L, Orozco O, Abrams T, Cantagallo L, Connor A, Desai J, Ebersbach H, Gelderblom H, Hoffmaster K, Lees E, et al. Mechanistic insights of an immunological adverse event induced by an anti-KIT antibody drug conjugate and mitigation strategies. Clin Cancer Res. 2018;24:3465–74. doi:10.1158/1078-0432.CCR-17-3786. PMID: 29615457.
   PubMed Web of Science ®Google Scholar
• Rosenthal M, Curry R, Reardon DA, Rasmussen E, Upreti VV, Damore MA, Henary HA, Hill JS, Cloughesy T. Safety, tolerability, and pharmacokinetics of anti-EGFRvIII antibody-drug conjugate AMG 595 in patients with recurrent malignant glioma expressing EGFRvIII. Cancer Chemother Pharmacol. 2019;84:327–36. doi:10.1007/s00280-019-03879-2. PMID: 31154523.
   PubMed Web of Science ®Google Scholar
• Duca M, Lim DW, Subbiah V, Takahashi S, Sarantopoulos J, Varga A, D’Alessio JA, Abrams T, Sheng Q, Tan EY, et al. A first-in-human, phase I, multicenter, open-label, dose-escalation study of PCA062: an antibody-drug conjugate targeting P-cadherin, in patients with solid tumors. Mol Cancer Ther. 2022;21:625–34. doi:10.1158/1535-7163.MCT-21-0652. PMID: 35131875.
   PubMed Web of Science ®Google Scholar
• Milowsky MI, Galsky MD, Morris MJ, Crona DJ, George DJ, Dreicer R, Tse K, Petruck J, Webb IJ, Bander NH, et al. Phase 1/2 multiple ascending dose trial of the prostate-specific membrane antigen-targeted antibody drug conjugate MLN2704 in metastatic castration-resistant prostate cancer. Urol Oncol. 2016;34(12):530 e515–530 e521. doi:10.1016/j.urolonc.2016.07.005. PMID: 27765518.
   Web of Science ®Google Scholar
• Lee HC, Raje NS, Landgren O, Upreti VV VV, Wang J, Avilion AA, Hu X, Rasmussen E, Ngarmchamnanrith G, Fujii H, et al. Phase 1 study of the anti-BCMA antibody-drug conjugate AMG 224 in patients with relapsed/refractory multiple myeloma. Leukemia. 2021;35(1):255–58. doi:10.1038/s41375-020-0834-9. PMID: 32317775.
   PubMed Web of Science ®Google Scholar
• Schoffski P, Concin N, Suarez C, Subbiah V, Ando Y, Ruan S, Wagner JP, Mansfield K, Zhu X, Origuchi S, et al. A phase 1 study of a CDH6-targeting antibody-Drug conjugate in patients with advanced solid tumors with evaluation of inflammatory and neurological adverse events. Oncol Res Treat. 2021;44:547–56. doi:10.1159/000518549. PMID: 34515215.
   PubMed Web of Science ®Google Scholar
• Kollmannsberger C, Britten CD, Olszanski AJ, Walker JA, Zang W, Willard MD, Radtke DB, Farrington DL, Bell-McGuinn KM, Patnaik A. A phase 1 study of LY3076226, a fibroblast growth factor receptor 3 (FGFR3) antibody–drug conjugate, in patients with advanced or metastatic cancer. Invest New Drugs. 2021;39(6):1613–23.doi:10.1007/s10637-021-01146-x. PMID: 34264412.
   PubMed Web of Science ®Google Scholar
• Trneny M, Verhoef G, Dyer MJ, Ben Yehuda D, Patti C, Canales M, Lopez A, Awan FT, Montgomery PG, Janikova A, et al. A phase II multicenter study of the anti-CD19 antibody drug conjugate coltuximab ravtansine (SAR3419) in patients with relapsed or refractory diffuse large B-cell lymphoma previously treated with rituximab-based immunotherapy. Haematologica. 2018;103(8):1351–58. doi:10.3324/haematol.2017.168401. PMID: 29748443.
   PubMed Web of Science ®Google Scholar
• Coiffier B, Thieblemont C, de Guibert S, Dupuis J, Ribrag V, Bouabdallah R, Morschhauser F, Navarro R, Le Gouill S, Haioun C, et al. A phase II, single-arm, multicentre study of coltuximab ravtansine (SAR3419) and rituximab in patients with relapsed or refractory diffuse large B-cell lymphoma. Br J Haematol. 2016;173(5):722–30. doi:10.1111/bjh.13992. PMID: 27010483.
   PubMed Web of Science ®Google Scholar
• Kantarjian HM, Lioure B, Kim SK, Atallah E, Leguay T, Kelly K, Marolleau J-P, Escoffre-Barbe M, Thomas XG, Cortes J, et al. A phase II study of coltuximab ravtansine (SAR3419) monotherapy in patients with relapsed or refractory acute lymphoblastic leukemia. Clin Lymphoma Myeloma Leuk. 2016;16(3):139–45. doi:10.1016/j.clml.2015.12.004. PMID: 26775883.
   PubMed Web of Science ®Google Scholar
• Lapusan S, Vidriales MB, Thomas X, de Botton S, Vekhoff A, Tang R, Dumontet C, Morariu-Zamfir R, Lambert JM, Ozoux ML, et al. Phase I studies of AVE9633, an anti-CD33 antibody-maytansinoid conjugate, in adult patients with relapsed/refractory acute myeloid leukemia. Invest New Drugs. 2012;30:1121–31. doi:10.1007/s10637-011-9670-0. PMID: 21519855.
   PubMed Web of Science ®Google Scholar
• Hong R, Xia W, Wang L, Lee K, Lu Q, Jiang K, Li S, Yu J, Wei J, Tang W, et al. Safety, tolerability, and pharmacokinetics of BAT8001 in patients with HER2-positive breast cancer: an open- label, dose-escalation, phase I study. Cancer Commun (Lond). 2021;41:171–82. doi:10.1002/cac2.12135. PMID: 33528890.
   PubMed Web of Science ®Google Scholar
• Pegram MD, Hamilton EP, Tan AR, Storniolo AM, Balic K, Rosenbaum AI, Liang M, He P, Marshall S, Scheuber A, et al. First-in-human, phase 1 dose-escalation study of biparatopic anti-HER2 antibody-drug conjugate MEDI4276 in patients with HER2-positive advanced breast or gastric cancer. Mol Cancer Ther. 2021;20:1442–53. doi:10.1158/1535-7163.MCT-20-0014. PMID: 34045233.
   PubMed Web of Science ®Google Scholar
• Morgensztern D, Johnson M, Rudin CM, Rossi M, Lazarov M, Brickman D, Fong A. SC-002 in patients with relapsed or refractory small cell lung cancer and large cell neuroendocrine carcinoma: phase 1 study. Lung Cancer. 2020;145:126–31. doi:10.1016/j.lungcan.2020.04.017. PMID: 32438272.
   PubMed Web of Science ®Google Scholar
• Lewis G, Li G, Guo J, Yu SF, Fields C, Lee G, Zhang D, Dragovich P, Pillow T, Wei B, et al. Development of DHES0815A; a novel HER2-directed antibody-drug conjugate comprised of a reduced potency mono-alkylating agent linked to a domain I binding HER2 antibody. Research Square. 2022;Preprint. doi:10.21203/rs.3.rs-2322502/v1.
   Google Scholar
• Krop I, Hamilton E, Jung KH, Modi S, Kalinsky KM, Phillips G, Shi R, Monemi S, Mamounas M, Saad O, et al. A phase I dose-escalation study of DHES0815A, a HER2-targeting antibody-drug conjugate with a DNA monoalkylator payload, in patients with HER2-positive breast cancer. Cancer Res. 2022;82. doi:10.1158/1538-7445.SABCS21-P2-13-25.
   Web of Science ®Google Scholar
• Portillo S. AbbVie halts SC-007 development program in gastric cancer.ADC Review; 2018.
   Google Scholar
• Phillips T, Barr PM, Park SI, Kolibaba K, Caimi PF, Chhabra S, Kingsley EC, Boyd T, Chen R, Carret A-S, et al. A phase 1 trial of SGN-CD70A in patients with CD70-positive diffuse large B cell lymphoma and mantle cell lymphoma. Invest New Drugs. 2019;37(2):297–306. doi:10.1007/s10637-018-0655-0. PMID: 30132271.
   PubMed Web of Science ®Google Scholar
• Fathi AT, Erba HP, Lancet JE, Stein EM, Ravandi F, Faderl S, Walter RB, Advani AS, DeAngelo DJ, Kovacsovics TJ, et al. A phase 1 trial of vadastuximab talirine combined with hypomethylating agents in patients with CD33-positive AML. Blood. 2018;132:1125–33. doi:10.1182/blood-2018-03-841171. PMID: 30045838.
   PubMed Web of Science ®Google Scholar
• Stein EM, Walter RB, Erba HP, Fathi AT, Advani AS, Lancet JE, Ravandi F, Kovacsovics T, DeAngelo DJ, Bixby D, et al. A phase 1 trial of vadastuximab talirine as monotherapy in patients with CD33-positive acute myeloid leukemia. Blood. 2018;131(4):387–96. doi:10.1182/blood-2017-06-789800. PMID: 29196412.
   PubMed Web of Science ®Google Scholar
• Daver N, Salhotra A, Brandwein JM, Podoltsev NA, Pollyea DA, Jurcic JG, Assouline S, Yee K, Li M, Pourmohamad T, et al. A Phase I dose-escalation study of DCLL9718S, an antibody-drug conjugate targeting C-type lectin-like molecule-1 (CLL-1) in patients with acute myeloid leukemia. Am J Hematol. 2021;96:E175–E179. doi:10.1002/ajh.26136. PMID: 33617672.
   PubMed Web of Science ®Google Scholar
• Garrido-Laguna I, Krop I, Burris HA 3rd, Hamilton E, Braiteh F, Weise AM, Abu-Khalaf M, Werner TL, Pirie-Shepherd S, Zopf CJ, et al. First-in-human, phase I study of PF-06647263, an anti-EFNA4 calicheamicin antibody-drug conjugate, in patients with advanced solid tumors. Int J Cancer. 2019;145:1798–808. doi:10.1002/ijc.32154. PMID: 30680712.
   PubMed Web of Science ®Google Scholar
• Herbertson RA, Tebbutt NC, Lee F-T, MacFarlane DJ, Chappell B, Micallef N, Lee S-T, Saunder T, Hopkins W, Smyth FE, et al. Phase I biodistribution and pharmacokinetic study of Lewis Y–Targeting immunoconjugate CMD-193 in patients with advanced epithelial cancers. Clin Cancer Res. 2009;15(21):6709–15. doi:10.1158/1078-0432.CCR-09-0536. PMID: 19825951.
   PubMed Web of Science ®Google Scholar
• Chan SY, Gordon AN, Coleman RE, Hall JB, Berger MS, Sherman ML, Eten CB, Finkler NJ. A phase 2 study of the cytotoxic immunoconjugate CMB-401 (hCTM01-calicheamicin) in patients with platinum-sensitive recurrent epithelial ovarian carcinoma. Cancer Immunol Immunother. 2003;52:243–48. doi:10.1007/s00262-002-0343-x. PMID: 12669249.
   PubMed Web of Science ®Google Scholar
• Gillespie AM, Broadhead TJ, Chan SY, Owen J, Farnsworth AP, Sopwith M, Coleman RE. Phase I open study of the effects of ascending doses of the cytotoxic immunoconjugate CMB-401 (hCTMO1-calicheamicin) in patients with epithelial ovarian cancer. Ann Oncol. 2000;11(6):735–41.doi:10.1023/a:1008349300781. PMID: 10942064.
   PubMed Web of Science ®Google Scholar
• Rottey S, Clarke J, Aung K, Machiels J-P, Markman B, Heinhuis KM, Millward M, Lolkema M, Patel SP, de Souza P, et al. Phase I/IIa trial of BMS-986148, an Anti-mesothelin Antibody–drug conjugate, alone or in combination with nivolumab in patients with advanced solid tumors. Clin Cancer Res. 2022;28(1):95–105. doi:10.1158/1078-0432.CCR-21-1181. PMID: 34615718.
   PubMed Web of Science ®Google Scholar
• Owonikoko TK, Hussain A, Stadler WM, Smith DC, Kluger H, Molina AM, Gulati P, Shah A, Ahlers CM, Cardarelli PM, et al. First-in-human multicenter phase I study of BMS-936561 (MDX-1203), an antibody-drug conjugate targeting CD70. Cancer Chemother Pharmacol. 2016;77(1):155–62. doi:10.1007/s00280-015-2909-2. PMID: 26576779.
   PubMed Web of Science ®Google Scholar
• Cortes J, DeAngelo D, Wang E, Arana-Yi C, Zweidler-McKay P, Munteanu M, Andreu-Vieyra C, Erba H, Blum W, Traer E Initial results from a first-in-human study of IMGN779, a CD33-targeting antibody-drug conjugate (ADC) with Novel DNA alkylating activity, in Patients with Relapsed or Refractory AML. EHA Conference; 2017; Madrid, Spain.
   Google Scholar
• Dotan E, Cohen SJ, Starodub AN, Lieu CH, Messersmith WA, Simpson PS, Guarino MJ, Marshall JL, Goldberg RM, Hecht JR, et al. Phase I/II trial of Labetuzumab govitecan (Anti-CEACAM5/SN-38 antibody-drug conjugate) in patients with refractory or relapsing metastatic colorectal cancer. J Clin Oncol. 2017;35(29):3338–46. doi:10.1200/JCO.2017.73.9011. PMID: 28817371.
   PubMed Web of Science ®Google Scholar
• George S, Heinrich MC, Somaiah N, Tine BA, McLeod R, Laadem A, Cheng B, Nishioka S, Kundu MG, Qian X, et al. A phase 1, multicenter, open-label, first-in-human study of DS-6157a in patients (pts) with advanced gastrointestinal stromal tumor (GIST). J Clin Oncol. 2022;40(16_suppl):11512–11512. doi:10.1200/JCO.2022.40.16_suppl.11512.
   Google Scholar
• Janku F, Han SW, Doi T, Amatu A, Ajani JA, Kuboki Y, Cortez A, Cellitti SE, Mahling PC, Subramanian K, et al. Preclinical characterization and phase I study of an anti-HER2-TLR7 immune-stimulator antibody conjugate in patients with HER2+ malignancies. Cancer Immunol Res. 2022;10:1441–61. doi:10.1158/2326-6066.CIR-21-0722. PMID: 36129967.
   PubMed Web of Science ®Google Scholar
• Klempner SJ, Beeram M, Sabanathan D, Chan A, Hamilton E, Loi S, Oh D, Emens LA, Patnaik A, Kim JE, et al. Interim results of a Phase 1/1b study of SBT6050 monotherapy and pembrolizumab combination in patients with advanced HER2-expressing or amplified solid tumors. ESMO Conference. 2021; Paris, France* (Virtual meeting due to COVID)
   Google Scholar
• https://www.askgileadmedical.com/docs/trodelvy/trodelvy-incidence-and-management-of-rash.
   Google Scholar
• Lacouture ME, Patel AB, Rosenberg JE, O’Donnell PH. Management of dermatologic events associated with the Nectin-4-directed antibody-drug conjugate enfortumab vedotin. Oncologist. 2022;27:e223–e232. doi:10.1093/oncolo/oyac001. PMID: 35274723.
   PubMed Web of Science ®Google Scholar
• Faria M, Peay M, Lam B, Ma E, Yuan M, Waldron M, Mylott WR Jr, Liang M, Rosenbaum AI. Multiplex LC-MS/MS assays for clinical bioanalysis of MEDI4276, an antibody-drug conjugate of tubulysin analogue attached via cleavable linker to a biparatopic humanized antibody against HER-2. Antibodies (Basel). 2019;8 doi:10.3390/antib8010011. PMID: 31544817.
   PubMedGoogle Scholar
• Maderna A, Doroski M, Subramanyam C, Porte A, Leverett CA, Vetelino BC, Chen Z, Risley H, Parris K, Pandit J, et al. Discovery of cytotoxic dolastatin 10 analogues with N-terminal modifications. J Med Chem. 2014;57:10527–43. doi:10.1021/jm501649k. PMID: 25431858.
   PubMed Web of Science ®Google Scholar
• Cortes J, Kim SB, Chung WP, Im SA, Park YH, Hegg R, Kim MH, Tseng LM, Petry V, Chung CF, et al. Trastuzumab deruxtecan versus trastuzumab emtansine for breast cancer. N Engl J Med. 2022;386:1143–54. doi:10.1056/NEJMoa2115022. PMID: 35320644.
   PubMed Web of Science ®Google Scholar
• Narita Y, Muragaki Y, Kagawa N, Asai K, Nagane M, Matsuda M, Ueki K, Kuroda J, Date I, Kobayashi H, et al. Safety and efficacy of depatuxizumab mafodotin in Japanese patients with malignant glioma: a nonrandomized, phase 1/2 trial. Cancer Sci. 2021;112:5020–33. doi:10.1111/cas.15153. PMID: 34609773.
   PubMed Web of Science ®Google Scholar
• Clement PMJ, Dirven L, Eoli M, Sepulveda-Sanchez JM, Walenkamp AME, Frenel JS, Franceschi E, Weller M, Chinot O, De Vos F, et al. Impact of depatuxizumab mafodotin on health-related quality of life and neurological functioning in the phase II EORTC 1410/INTELLANCE 2 trial for EGFR-amplified recurrent glioblastoma. Eur J Cancer. 2021;147:1–12. doi:10.1016/j.ejca.2021.01.010. PMID: 33601293.
   PubMed Web of Science ®Google Scholar
• Berdeja JG, Hernandez-Ilizaliturri F, Chanan-Khan A, Patel M, Kelly KR, Running KL, Murphy M, Guild R, Carrigan C, Ladd S, et al. Phase I study of Lorvotuzumab Mertansine (LM, IMGN901) in combination with Lenalidomide (Len) and Dexamethasone (Dex) in patients with CD56-positive relapsed or relapsed/refractory Multiple Myeloma (MM). Blood. 2012;120:728. doi:10.1182/blood.V120.21.728.728.
   PubMed Web of Science ®Google Scholar
• Hamblett KJ, Barnscher SD, Davies RH, Hammond PW, Hernandez A, Wickman GR, Fung VK, Ding T, Garnett G, Galey AS, et al. ZW49, a HER2 targeted biparatopic antibody drug conjugate for the treatment of HER2 expressing cancers. Cancer Res. 2019;79:6–17-13. doi:10.1158/1538-7445.SABCS18-P6-17-13.
   Web of Science ®Google Scholar
• Knuehl C, Toleikis L, Dotterweich J, Ma J, Kumar S, Ross E, Wilm C, Schmitt M, Grote HJ, Amendt C. M1231 is a bispecific anti-MUC1xEGFR antibody-drug conjugate designed to treat solid tumors with MUC1 and EGFR co-expression. Cancer Res. 2022;82:5284. doi:10.1158/1538-7445.AM2022-5284.
   Google Scholar
• Mazor Y, Sachsenmeier KF, Yang C, Hansen A, Filderman J, Mulgrew K, Wu H, Dall’Acqua WF. Enhanced tumor-targeting selectivity by modulating bispecific antibody binding affinity and format valence. Sci Rep. 2017;7:40098. doi:10.1038/srep40098. PMID: 28067257.
   PubMed Web of Science ®Google Scholar
• Zhao H, Atkinson J, Gulesserian S, Zeng Z, Nater J, Ou J, Yang P, Morrison K, Coleman J, Malik F, et al. Modulation of macropinocytosis-mediated internalization decreases ocular toxicity of antibody-drug conjugates. Cancer Res. 2018;78:2115–26. doi:10.1158/0008-5472.CAN-17-3202. PMID: 29382707.
   PubMed Web of Science ®Google Scholar
• Viricel W, Fournet G, Beaumel S, Perrial E, Papot S, Dumontet C, Joseph B. Monodisperse polysarcosine-based highly-loaded antibody-drug conjugates. Chem Sci. 2019;10:4048–53. doi:10.1039/c9sc00285e. PMID: 31015945.
   PubMed Web of Science ®Google Scholar
• Burke PJ, Hamilton JZ, Jeffrey SC, Hunter JH, Doronina SO, Okeley NM, Miyamoto JB, Anderson ME, Stone IJ, Ulrich ML, et al. Optimization of a PEGylated glucuronide-monomethylauristatin E linker for antibody-drug conjugates. Mol Cancer Ther. 2017;16:116–23. doi:10.1158/1535-7163.MCT-16-0343. PMID: 28062707.
   PubMed Web of Science ®Google Scholar
• Evans N, Grygorash R, Williams P, Kyle A, Kantner T, Pathak R, Sheng X, Simoes F, Makwana H, Resende R, et al. Incorporation of hydrophilic macrocycles into drug-linker reagents produces antibody-drug conjugates with enhanced in vivo performance. Front Pharmacol. 2022;13:764540. doi:10.3389/fphar.2022.764540. PMID: 35784686.
   PubMed Web of Science ®Google Scholar
• Gandhi AV, Randolph TW, Carpenter JF. Conjugation of emtansine onto trastuzumab promotes aggregation of the antibody-drug conjugate by reducing repulsive electrostatic interactions and increasing hydrophobic interactions. J Pharm Sci. 2019;108:1973–83. doi:10.1016/j.xphs.2019.01.029. PMID: 30735687.
   PubMed Web of Science ®Google Scholar
• Yurkovetskiy AV, Bodyak ND, Yin M, Thomas JD, Clardy SM, Conlon PR, Stevenson CA, Uttard A, Qin L, Gumerov DR, et al. Dolaflexin: a novel antibody-drug conjugate platform featuring high drug loading and a controlled bystander effect. Mol Cancer Ther. 2021;20:885–95. doi:10.1158/1535-7163.MCT-20-0166. PMID: 33722857.
   PubMed Web of Science ®Google Scholar
• Zacharias N, Podust VN, Kajihara KK, Leipold D, Del Rosario G, Thayer D, Dong E, Paluch M, Fischer D, Zheng K, et al. A homogeneous high-DAR antibody-drug conjugate platform combining THIOMAB antibodies and XTEN polypeptides. Chem Sci. 2022;13:3147–60. doi:10.1039/d1sc05243h. PMID: 35414872.
   PubMed Web of Science ®Google Scholar
• Kovtun YV, Audette CA, Mayo MF, Jones GE, Doherty H, Maloney EK, Erickson HK, Sun X, Wilhelm S, Ab O, et al. Antibody-maytansinoid conjugates designed to bypass multidrug resistance. Cancer Res. 2010;70:2528–37. doi:10.1158/0008-5472.CAN-09-3546. PMID: 20197459.
   PubMed Web of Science ®Google Scholar
• Bryden F, Martin C, Letast S, Lles E, Vieitez-Villemin I, Rousseau A, Colas C, Brachet-Botineau M, Allard-Vannier E, Larbouret C, et al. Impact of cathepsin B-sensitive triggers and hydrophilic linkers on in vitro efficacy of novel site-specific antibody-drug conjugates. Org Biomol Chem. 2018;16:1882–89. doi:10.1039/c7ob02780j. PMID: 29473076.
   PubMed Web of Science ®Google Scholar
• Chuprakov S, Ogunkoya AO, Barfield RM, Bauzon M, Hickle C, Kim YC, Yeo D, Zhang F, Rabuka D, Drake PM. Tandem-cleavage linkers improve the in vivo stability and tolerability of antibody-drug conjugates. Bioconjug Chem. 2021;32:746–54. doi:10.1021/acs.bioconjchem.1c00029. PMID: 33689309.
   PubMed Web of Science ®Google Scholar
• Weidle UH, Tiefenthaler G, Georges G. Proteases as activators for cytotoxic prodrugs in antitumor therapy. Cancer Genomics Proteomics. 2014;11:67–79. https://www.ncbi.nlm.nih.gov/pubmed/24709544. PMID: 24709544.
   PubMed Web of Science ®Google Scholar
• Gregson SJ, Barrett AM, Patel NV, Kang GD, Schiavone D, Sult E, Barry CS, Vijayakrishnan B, Adams LR, Masterson LA, et al. Synthesis and evaluation of pyrrolobenzodiazepine dimer antibody-drug conjugates with dual beta-glucuronide and dipeptide triggers. Eur J Med Chem. 2019;179:591–607. doi:10.1016/j.ejmech.2019.06.044. PMID: 31279293.
   PubMed Web of Science ®Google Scholar
• Tsui CK, Barfield RM, Fischer CR, Morgens DW, Li A, Smith BAH, Gray MA, Bertozzi CR, Rabuka D, Bassik MC. CRISPR-Cas9 screens identify regulators of antibody-drug conjugate toxicity. Nat Chem Biol. 2019;15:949–58. doi:10.1038/s41589-019-0342-2. PMID: 31451760.
   PubMed Web of Science ®Google Scholar
• Satomaa T, Pynnonen H, Vilkman A, Kotiranta T, Pitkanen V, Heiskanen A, Herpers B, Price LS, Helin J, Saarinen J. Hydrophilic auristatin glycoside payload enables improved antibody-drug conjugate efficacy and biocompatibility. Antibodies (Basel). 2018;7 doi:10.3390/antib7020015. PMID: 31544867.
   PubMedGoogle Scholar
• Levengood MR, Zhang X, Hunter JH, Emmerton KK, Miyamoto JB, Lewis TS, Senter PD. Orthogonal cysteine protection enables homogeneous multi-drug antibody-drug conjugates. Angew Chem Int Ed Engl. 2017;56:733–37. doi:10.1002/anie.201608292. PMID: 27966822.
   PubMed Web of Science ®Google Scholar
• Kumar A, Kinneer K, Masterson L, Ezeadi E, Howard P, Wu H, Gao C, Dimasi N. Synthesis of a heterotrifunctional linker for the site-specific preparation of antibody-drug conjugates with two distinct warheads. Bioorg Med Chem Lett. 2018;28:3617–21. doi:10.1016/j.bmcl.2018.10.043. PMID: 30389292.
   PubMed Web of Science ®Google Scholar
• Nilchan N, Li X, Pedzisa L, Nanna AR, Roush WR, Rader C. Dual-mechanistic antibody-drug conjugate via site-specific selenocysteine/cysteine conjugation. Antib Ther. 2019;2:71–78. doi:10.1093/abt/tbz009. PMID: 31930187.
   PubMedGoogle Scholar
• Yamazaki CM, Yamaguchi A, Anami Y, Xiong W, Otani Y, Lee J, Ueno NT, Zhang N, An Z, Tsuchikama K. Antibody-drug conjugates with dual payloads for combating breast tumor heterogeneity and drug resistance. Nat Commun. 2021;12:3528. doi:10.1038/s41467-021-23793-7. PMID: 34112795.
   PubMed Web of Science ®Google Scholar
• Walsh SJ, Bargh JD, Dannheim FM, Hanby AR, Seki H, Counsell AJ, Ou X, Fowler E, Ashman N, Takada Y, et al. Site-selective modification strategies in antibody-drug conjugates. Chem Soc Rev. 2021;50:1305–53. doi:10.1039/d0cs00310g. PMID: 33290462.
   PubMed Web of Science ®Google Scholar
• Yin G, Stephenson HT, Yang J, Li X, Armstrong SM, Heibeck TH, Tran C, Masikat MR, Zhou S, Stafford RL, et al. RF1 attenuation enables efficient non-natural amino acid incorporation for production of homogeneous antibody drug conjugates. Sci Rep. 2017;7:3026. doi:10.1038/s41598-017-03192-z. PMID: 28596531.
   PubMed Web of Science ®Google Scholar
• Liu J, Barfield RM, Rabuka D. Site-specific bioconjugation using SMARTag((R)) technology: a practical and effective chemoenzymatic approach to generate antibody-drug conjugates. Methods Mol Biol. 2019;2033:131–47. doi:10.1007/978-1-4939-9654-4_10. PMID: 31332752.
   PubMedGoogle Scholar
• Strop P, Liu S-H, Dorywalska M, Delaria K, Dushin RG, Tran -T-T, Ho W-H, Farias S, Casas MG, Abdiche Y, et al. Location matters: site of conjugation modulates stability and pharmacokinetics of antibody drug conjugates. Chem Biol. 2013;20(2):161–67. doi:10.1016/j.chembiol.2013.01.010. PMID: 23438745.
   PubMed Web of Science ®Google Scholar
• Van Geel R, Wijdeven MA, Heesbeen R, Verkade JM, Wasiel AA, Van Berkel SS, van Delft FL. Chemoenzymatic conjugation of toxic payloads to the globally conserved N-glycan of native mAbs provides homogeneous and highly efficacious antibody–Drug conjugates. Bioconjug Chem. 2015;26(11):2233–42.doi:10.1021/acs.bioconjchem.5b00224. PMID: 26061183.
   PubMed Web of Science ®Google Scholar
• Ferrara C, Grau S, Jager C, Sondermann P, Brunker P, Waldhauer I, Hennig M, Ruf A, Rufer AC, Stihle M, et al. Unique carbohydrate–carbohydrate interactions are required for high affinity binding between FcγRIII and antibodies lacking core fucose. Proc Natl Acad Sci U S A. 2011;108(31):12669–74. doi:10.1073/pnas.1108455108. PMID: 21768335.
   PubMed Web of Science ®Google Scholar